🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains

Published 16/04/2024, 09:31
© Reuters. FILE PHOTO: The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in Shanghai, China February 1, 2019. Picture taken February 1, 2019. REUTERS/Stringer/File Photo
LLY
-
BAYGN
-
AZN
-

By Patricia Weiss and Ludwig Burger

INGELHEIM, Germany (Reuters) - Boehringer Ingelheim on Tuesday overtook Bayer (ETR:BAYGN) as Germany's largest drugmaker when the unlisted company reported a currency-adjusted gain in 2023 pharmaceutical sales of 10.3% to 20.8 billion euros ($22.11 billion).

Diversified rival Bayer reported in March that 2023 sales at its pharmaceuticals division slipped 6% to 18.1 billion euros, as gains from prostate cancer drug Nubeqa and kidney drug Kerendia were offset by declines in China.

Growth at Boehringer's pharma unit, driven by diabetes drug Jardiance and lung drug Ofev, pushed 2023 group sales, also including its animal health business, up 9.7% at constant currencies to 25.6 billion euros.

Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly (NYSE:LLY), made 7.4 billion euros in annual sales, a currency-adjusted surge of 31%. Jardiance, used to treat diabetes, heart failure and chronic kidney disease, competes with AstraZeneca (NASDAQ:AZN)'s Farxiga.

Sales of pulmonary fibrosis drug Ofev rose a currency-adjusted 12.8% to 3.5 billion euros, Boehringer said.

Boehringer is in a collaboration with Denmark's Zealand Pharma to develop a weight loss drug that the partners hope can be launched in 2027 or 2028, to compete with Lilly's recently launched obesity drug Mounjaro.

© Reuters. FILE PHOTO: The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in Shanghai, China February 1, 2019. Picture taken February 1, 2019. REUTERS/Stringer/File Photo

For 2024, Boehringer said it expects a slight increase in group revenues, adjusted for currency swings and one-off effects.

($1 = 0.9409 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.